Orphan-drug designation for Nav1.7 blocking pain drug CNV1014802 granted

Convergence Pharmaceuticals Limited, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation* by the US Food and Drug Administration for the treatment of trigeminal neuralgia (TN). TN is a very severe form of facial pain that is experienced in short bursts or attacks called paroxysms...
Pain / Anesthetics News From Medical News Today

Related Content